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In recent years a strong trend towards continuous biopharmaceutical processing has gathered momentum, 
driven by the promise of process intensification, reduced cost of goods, and more consistent and better 
controlled product quality. Key technologies in upstream cell culture (ATF, TFF) have enabled the start of a shift 
towards process intensification/continuous processing in the seed train (N-1 perfusion) and main production 
culture (concentrated fed-batch, perfusion) for biopharmaceutical production processes. While these 
technologies are now available for large scale bioreactor operations, small-scale application is limited to 
traditional benchtop bioreactor scales and formats. Benchtop bioreactors do provide a route to developing this 
new wave of intensified/continuous cell culture processes, however this approach is manually intensive, 
relatively low throughput and cost-intensive to operate. In the last 5 years, fed-batch cell culture process 
development has been significantly accelerated by wide spread implementation of the ambr 15 and ambr 250 
fully automated, single-use, micro and mini bioreactor systems. Case studies will be presented on the utility of 
the ambr 15 as a perfusion mimic, and we also present here the first publication of a new version of the ambr 
250 system currently in development ‘ambr 250 perfusion’. Technical description and operating data presented 
for the novel ‘ambr 250 perfusion’ system outline the capacity and capability of this technology. As established 
with ambr 250 for fed-batch processes, ambr 250 perfusion has the potential to provide the industry with a step 
change in perfusion process development capacity, enabling implementation of DoE based approaches for 
process optimization and characterization. It is envisaged that ‘ambr 250 perfusion’ can therefore facilitate and 
significantly accelerate an industry wide transition to upstream cell culture perfusion processes for novel 
biopharmaceuticals currently in early development. 
 
 
 
 
